GB1536425A - Blood treatment - Google Patents

Blood treatment

Info

Publication number
GB1536425A
GB1536425A GB5101/75A GB510175A GB1536425A GB 1536425 A GB1536425 A GB 1536425A GB 5101/75 A GB5101/75 A GB 5101/75A GB 510175 A GB510175 A GB 510175A GB 1536425 A GB1536425 A GB 1536425A
Authority
GB
United Kingdom
Prior art keywords
substance
biocompatible
support material
concentration
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5101/75A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Development Corp UK
Original Assignee
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK
Priority to GB5101/75A priority Critical patent/GB1536425A/en
Publication of GB1536425A publication Critical patent/GB1536425A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

1536425 Blood purification NATIONAL RESEARCH DEVELOPMENT CORP 30 Jan 1976 [6 Fob 1975] 5101/75 Heading C3H A biocompatible material for removing from blood an undesirable substance capable of being bound to a plasma protein comprises a support material rendered biocompatible by a coating of a biocompatible substance, which support material is a manoreticular polymer having an affinity for one or more of the substances unconjugated bilirubin, cholic acid, chenodeoxycholic acid and lithocholic acid. The biocompatible substance is preferably a plasma constituent, e.g. HSA. The affinity of the support material is preferably such that the concentration of one of the substances unconjugated bilirubin, cholic acid, chenodeoxycholic acid and lithocholic acid on the uncoated support material at equilibrium with a 15 mg. per cent solution of the substance in normal human plasma at pH 7.4 is at least 10% of the concentration of the substance on the coated material under identical conditions. The concentration of one of said substances on the uncoated support material may be at least 20% of the concentration of the substance on the coated material under said conditions. The biocompatible material may have a water content which is no greater than 80% by weight, and it is preferably particulate. A biocompatible material according to any preceding claim in which the support material is a synthetic resin, e.g. methacrylic or acrylic polymer or copolymer.
GB5101/75A 1976-01-30 1976-01-30 Blood treatment Expired GB1536425A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB5101/75A GB1536425A (en) 1976-01-30 1976-01-30 Blood treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5101/75A GB1536425A (en) 1976-01-30 1976-01-30 Blood treatment

Publications (1)

Publication Number Publication Date
GB1536425A true GB1536425A (en) 1978-12-20

Family

ID=9789761

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5101/75A Expired GB1536425A (en) 1976-01-30 1976-01-30 Blood treatment

Country Status (1)

Country Link
GB (1) GB1536425A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437861A (en) * 1993-03-16 1995-08-01 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome
US5523096A (en) * 1993-03-16 1996-06-04 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components
WO1996016666A1 (en) * 1994-11-30 1996-06-06 Sanitaria Scaligera S.P.A. Method for the specific immunoadsorption of selected pathogenic factors
WO2006138698A3 (en) * 2005-06-17 2007-05-31 Univ Maryland Biotech Inst Metal-enhanced fluorescence-based sensing methods

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437861A (en) * 1993-03-16 1995-08-01 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome
US5523096A (en) * 1993-03-16 1996-06-04 Applied Immune Sciences, Inc. Removal of selected factors from whole blood or its components
US5730713A (en) * 1993-03-16 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Removal of selected factors from whole blood or its components
WO1996016666A1 (en) * 1994-11-30 1996-06-06 Sanitaria Scaligera S.P.A. Method for the specific immunoadsorption of selected pathogenic factors
US8759110B2 (en) 2002-11-26 2014-06-24 University Of Maryland, Baltimore County Metal enhanced fluorescence-based sensing methods
WO2006138698A3 (en) * 2005-06-17 2007-05-31 Univ Maryland Biotech Inst Metal-enhanced fluorescence-based sensing methods
US7939333B2 (en) 2005-06-17 2011-05-10 University Of Maryland, Baltimore County Metal enhanced fluorescence-based sensing methods

Similar Documents

Publication Publication Date Title
EP0065069A3 (en) Latex for immobilizing biologically active substances
ATE88097T1 (en) METHOD AND SYSTEM FOR REMOVAL OF IMMUNOSUPRESSIVE COMPONENTS FROM MAMMALIAN BLOOD.
Spieker-Polet et al. Identification of albumin as the serum factor essential for the growth of activated human lymphocytes.
Lotan et al. Enhancement of the biological activities of soybean agglutinin by cross-linking with glutaraldehyde
ATE421319T1 (en) ERYTHROCYTES ENRICHED WITH S-NITROSOTHIOL AND THEIR USE
O'Brien et al. Periodate-Induced Lymphocyte Transformation: IV. Mitogenic Effect of NaIO4 Treated Lymphocytes Upon Autologous Lymphocytes
GB1536425A (en) Blood treatment
Sugimoto et al. Differential acceleration by hydrocortisone of the accumulation of epidermal structural proteins in the chick embryonic skin growing in a chemically defined medium
Belousov The use of magnetite nanoparticles in applied medicine
Schiffmann et al. The role of the matrix in aortic calcification
ATE263779T1 (en) AQUEOUS PROTEIN COMPOSITION, CONTAINING GLYCOPROTEINS, METHOD FOR PRODUCTION AND USES
Gibbons et al. A method for the separation of hybrids of chromatographically identical oligomeric proteins. Use of 3, 4, 5, 6-tetrahydrophthaloyl groups as a reversible" chromatographic handle"
Rapoport et al. Effects of atriopeptins on relaxation and cyclic GMP levels in rat and rabbit aortas
DE69427745D1 (en) TUMOR TREATMENT DEVICE USING SELECTIVE PROTEIN REDUCTION
Lawless et al. Is leucine an allosteric modulator of the lysine transporter in the intestinal basolateral membrane?
EP0030363B1 (en) Process for obtaining alpha-2-sb-glycoprotein
ATE44750T1 (en) PROCESS FOR PREPARING AN ANTI-HEMOPHILIA FACTOR CONCENTRATE.
Lea et al. The binding of testosterone to different serum proteins: A comparative study
KR890004673A (en) Glass microbeads having bactericidal properties and a method for producing the same.
DE3109123A1 (en) Process for the covalent immobilisation of biological detoxification systems on artificial surfaces
CH664496A5 (en) MATERIAL FOR REMOVING IMMUNE COMPLEXES FROM BLOOD OR PLASMA.
Fehm et al. Influence of plasma on ACTH stimulated corticosterone production of isolated adrenal cells
Huet et al. Peroxidase binding to cell-bound Concanavalin A
Panikkar et al. Modified Polyacrylamide Microspheres as Immunosorbent: Trivandrum-695012. India.
Myant et al. Observations on filter-paper electrophoresis of thyroxine in barbiturate buffer

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee